KalVista (KALV) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion recommending marketing authorization for sebetralstat, a novel oral plasma kallikrein inhibitor, for symptomatic treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older. The European Commission final decision is expected by early October.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Buy Rating for KalVista Pharmaceuticals: Strong Growth Potential Following Ekterly’s FDA Approval and Strategic Financial Positioning
- KalVista announces MHRA approval of Ekterly
- KalVista Pharmaceuticals: EKTERLY Launch and Financial Update
- KalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position
- Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges